Navigation Links
FREE FAT CELL ASSAY

Susanne Rasmussen, Anders R. Srensen Novo Nordisk A/S

Introduction

The free fat cell assay has been used extensively to demonstrate the effect of insulin and insulin analogues on target tissue (1,2). The principle of the assay has been described by Rodbell(3) and Moody et al(4). The assay uses isolated adipocytes from either mice or rats. When stimulated by insulin, the adipocytes incorporate glucose into fat depots, and a suitably labelled glucose added to the medium will result in incorporation of radioactivity into the lipid pool. Extraction of the lipids from the cells has traditionally been performed using a toluene-based scintillator. The phase separation in this system is so effective that direct liquid scintillation counting of the sample is possible without further preparation. The counts originating from the aqueous phase, which still contains a considerable amount of radio labelled glucose, are negligible. Previously, the scintillators that were available for use in the TopCount microplate scintillation and luminescence counter did not have the preferred characteristics for the phase separation, so the toluene scintillator method, with its many undesirable chemical and physical properties, continued to be used. However, the availability of MicroScint-E scintillator from Packard Instrument Company now makes it possible to discontinue the use of toluene-based scintillator solutions, and count samples prepared with MicroScint- E directly in the TopCount.

Method

Animals are killed, and the epididymal fat pads are removed and placed in degradation buffer. Degradation is carried out at 37 C under vigorous shaking for one hour. The cell suspension is filtered in order to remove tissue debris, and the adipocytes are washed twice and resuspended in incubation buffer.

Using the 96-well microplate format, 100 μL of cell suspensio n per sample is incubated with 10 μL glucose solution and 10 μL insulin for two hours at 37 C using gentle shaking. The incubation is stopped by adding 150 μL of MicroScint-E scintillator, and counted.

Materials

Collagenase is obtained from Wellington, radio labelled D-3-3H-glucose is from Amersham Pharmacia Biotech, and human serum albumin is from Behring Diagnostics GmbH. MicroScint-E is obtained from Packard Instrument Company. All other chemicals are analytical grade or higher.

Buffers:

Weltmans Reagent: 66.2 g CaCl22 H2O, Water ad 1000 mL.

Krebs Stock: 32.26 g NaCl, 1.77 g KCl, 0.811 g KH2PO4, 1.469 g MgSO47H2O, 28 mL Weltmans Reagent, water ad 1000 mL.

10% Human Serum Albumin (HSA): 52.5 g HSA is dissolved in 250 mL water. Add 26.25 g activated charcoal and let it stand for at least 4 hours (room temperature). Shake occasionally. Filter mixture to remove charcoal and dialyse to remove ions. Dilute to 500 mL.

Hepes pH 7.9: 11.92 g Hepes is dissolved in 50 mL water. Adjust pH to 7.9 using 1N NaOH. Dilute to 100 mL. Hepes Buffer: 40 mL Krebs, 50 mL 10% HSA, 10 mL 0.5M Hepes pH 7.9 Water ad 200 mL.

Incubation Buffer: 100 mL Krebs, 50 mL 10% HSA, 25 mL Hepes pH 7.9, water ad 500 mL.

Degradation Buffer: 4 mg collagenase, 2 mg glucose, 4 mL 10 % HSA, 2 mL Krebs, 0.5 mL Hepes pH 7.9, 3.5 mL water.

Glucose Solution: 12.5 μL D(3H3) glucose 1 mg glucose 1 mL Hepes buffer.

Results

Extraction of only the lipids is crucial for the interpretation of the insulin action, and the results from MicroScint-E extraction pro ved to be comparable to those from using the toluene scintillator extraction system. Using the same batch of cells for comparing the two extraction systems gave ED50 of 103 10 pM for toluene scintillator and 97 7 pM for MicroScint-E. The full dose response curves are shown in Figure 1.

Conclusion

The MicroScint-E scintillator from Packard Instrument Company provides the characteristics necessary to extract and count free fat cell assay samples in 96-well microplates in the TopCount without physically removing the aqueous phase. This heterogeneous counting method simplifies the assay, and enables rapid preparation and multiple-detector counting of such assays. MicroScint-E also eliminates the hazardous properties of toluene scintillator system, which was formerly the extractant of choice.

References

1) Brange J, Ribel U, Hansen JF, Havelund S, Melberg SG, Norris F, Norris K, Snel L, Srensen AR, Voigt HO (1988). Nature, 333, 679-682.

2) Vlund Aa, Brange J, Drejer K, Jensen I, Markussen J, Ribel U, Srensen AR, Schlichtkrull J. Diabetic Medicine 1991; 8: 839-847.

3) Martin Rodbell. (1964). The Journal of Biological Chemistry. 239(2).375-380.

4) A. J. Moody, M. A. Stan, M. Stan. (1974), Horm.Metab.Res.6.12-16.


'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. DELFIA Protein Kinase assays.
2. A Positive Selection Assay for Mutation Analysis in Big Blue Animals
3. Luminol-enhanced Assay for Superoxide Anion (O2 face="Symbol" )
4. Organize Your Data from the Big Blue Mutation Assay
5. Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations
6. RNase Protection Assay (RPA) Using DIG-Labeled RNA Probes
7. measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay
8. Matched siRNAs and Assays: Ambion + Applied Biosystems = RNAi Success
9. Using Validated siRNAs in Functional Genomic Assays
10. Nuclease Protection Assays: The Basics
11. RNArticles: RNA Amplification Used to Develop a New In Vitro HCMV Assay
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/24/2017)... 2017   Instrument Business Outlook ( ... MN ) the 2016 Company of the ... newsletter tracking developments in the analytical and life ... consistently achieved outstanding technical, operational and financial results ... of IBO. "In 2016, Bio-Techne capitalized on opportunities ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... company announces significant growth last year adding 65 new US and international facilities ... Army medical centers as well as one of US largest imaging center chains. ...
(Date:1/23/2017)... 23, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the ... New Zealand based Phase 1 ... showed remarkable results in reducing inflamed protein biomarkers in ... It is believed that this is the first time ... type can be made between epigenetic regulation and its ...
(Date:1/23/2017)... Calif. , Jan. 23, 2017  Alkahest ... innovative treatments for neurodegenerative diseases and other age-related ... joined the company as Chief Medical Officer. In ... and clinical development activities at Alkahest and serve ... Jackson most recently served as Executive Director at ...
Breaking Biology Technology:
(Date:12/22/2016)... -- As part of its longstanding mission to improve genetic literacy ... released its latest children,s book, titled The One ... topics of inheritance and variation of traits that are part ... school classrooms in the US. The book ... Killoran , whose previous book with 23andMe, You ...
(Date:12/20/2016)... 2016 The rising popularity of mobility ... is stoking significant interest in keyless access systems. ... low energy (BLE), biometrics and near-field communication (NFC) ... of wireless technologies in the automotive industry. This ... access systems opens the market to specialist companies ...
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
Breaking Biology News(10 mins):